Back to search

Aristotle University Of Thessaloniki (AUTH)

Ο ρόλος των μεταλλοπρωτεϊνασών-2 και -9 στην αθηροσκλήρωση των ασθενών με χρόνια νεφρική νόσο

Abstract

dc:description

Cardiovascular disease is the major cause of morbidity and mortality among patients with chronic kidney disease (CKD) especially in end-stage renal disease (ESRD). CKD is recognized by the presence of persistent proteinuria or renal dysfunction and several recent studies have reported that proteinuria is not just a marker of CKD, but that it could also cause renal damage in patients with CKD. Further, there is accumulating evidence that proteinuria is an independent risk factor for cardiovascular disease (CVD) as well. These observations suggest the link of proteinuria to CKD and CVD. However, the underlying mechanisms by which proteinuria could cause renal and vascular damage in patients with CKD are not yet well investigated.Diabetic nephropathy (DN) and primary chronic glomerulonephritis (CGN) represent the most important causes of ESRD but the exact underlying mechanisms of their pathogenesis and progression are not completely elucidated. The histological changes including glomerular hypertrophy, glomerular basement membrane (GBM) thickening and mesangial expansion, involve the remodeling of the extracellular matrix (ECM).The major physiologic regulators of ECM degradation are matrix metalloproteinases (MMPs). Collagen type-IV (col-IV) is the main collagenous component of ECM that constitutes the architectural structure of the vessel basement membrane (BM) and the GBM. BM is the part of ECM which is associated with the vascular endothelium. Both MMPs-2 and -9 are the main enzymes that degrade col-IV and they have recently been involved in atherosclerosis, as well as in CVD and CKD.Until the protocol design of this thesis there were only very few clinical data with inconsistent and controversial results from previous clinical studies correlating both MMP-2 and MMP-9 with atherosclerosis and especially in CKD while the studies included patients in advanced and end-stage of CKD. There were no data found evaluating the correlation of MMPs -2 and -9 with proteinuria. The only study correlation of MMP-2 with albuminuria, even recent time presentation with the beginning of the present study, included patients of advanced stages of CKD with various causes of the disease, and many of them didn’t present proteinuria.In this context, the primary aim of the present doctoral thesis was to investigate the involvement of MMPs -2 and -9 in the pathophysiological mechanisms linking albuminuria to atherosclerosis (carotid and femoral arteries) in CKD. Thus, atherosclerosis was examined by its early marker of IMT (intima-media thickness), the presence of atherosclerotic plaque and the result of ATHUS (atherosclerotic ultrasonic score) for all four vessels (ATHUS: 0-8, IMT <0.8mm = 0, ΙΜΤ≥0.8 = 1, absence of atherosclerotic plaque = 0 and presence of stenotic atherosclerotic plaque >25% = 1).Secondary aims of this study were to correlate those two gelatinases, MMPs -2 and -9 with hypertension (HT), body mass index (BMI), hyperuricemia biomarkers of malnutrition, inflammatory biomarkers, oxidative stress. MMPs -2 and -9 were also correlated with growth factors as TGF-β1 and VEGF-A in order to highlight another mechanism of pathogenesis and progression of CKD, which may affect the quality of life of these patients.In the present study, 160 patients of early and advanced stages of CKD were included, and 66 patients of 4th and ESRD, without being integrated into the haemodialysis program (GFR: 12-25 ml/min/1.73m2). All patients were divided into two groups according to the cause of CKD. Thus, 80 patients presented with DN from diabetes mellitus type 2 (DM2), 20 in each stage of CKD (I-IV) and 80 patients were presented with CGN (20 in each stage I-IV) including minimal change GN (MCGN), mesangioproliferative GN (MPGN), IgAN, membranous GN (MGN), and focal segmental GN (FSGN). As controls there were 112 persons divided into two groups, 56 patients with diabetes melitus type 2, without CKD, suffering from DM for more than 15 years, and 56 healthy individuals volunteers who didn’t receive any medication. Similarly were divided the other 66 patients, of advanced stages of CKD and ESRD, 33 with DN from DM2 and 33 with CGN. Thus, we tested the problem of proteinuria by two different pathways, a non-inflammatory cause of CKD (DN) and an inflammatory cause (CGN), and from the early stages of CKD advancing to the progression of the disease. A group of 44 patients who were hospitalized and attended for temporal arteritis and were negative for the disease, served as controls. The above patient and control groups were performed three different laboratory methods in order to clarify the role of both MMPs -2 and -9 in atherosclerosis and albuminuria in CKD. In the first case were determined the serum levels of MMPs -2 and -9 with their inhibitors TIMPs-1 and -2 by an enzyme-linked immunosorbent assay (ELISA) for the whole of 160 patients. Then in these patients was conducted genotypic analysis for five single nucleotide polymorphisms (SNPs), three of MMP-2 (C735T, C1306T, G1575A) and two of MMP-9 (R279Q, C1562T) by the technique of polymerase chain reaction (PCR). All MMPs -2 and -9 SNPs were genotyped (genomic DNA was extracted from whole blood from those patients) with the KASPar method by buying services from KBioscience company. Finally, for the 66 patients of predialysis stage, during the process of arteriovenous fistula (AVF) creation sections of the radial artery were harvested for histological and immunohistochemical examination. The expression of MMP-2, MMP-9, TIMP-1 and TIMP-2 of all types of vascular cells (endothelial-ECs, smooth muscle cells-SMCs, fibroblasts-FBCs) was measured using immunohistochemical staining with anti-MMP-2, anti-MMP-9, anti-TIMP-1 and anti-TIMP-2 antibodies, during the process of veins arterialization.All laboratory methods and techniques were performed in AHEPA University Hospital of Thessaloniki (AHEPA UHT) laboratories of biochemistry and ultrasound of neurovascular diseases and the laboratory of pathology of Medical School of Aristotle University of Thessaloniki. All patients were hospitalized or attended at Outpatient Clinic of Renal Unit of 1st Propaedeutic Medical Department of Internal Medicine of AHEPA UHT.The present doctoral thesis provided a series of major results. Mean serum levels of MMP-2 and MMP-9 were statistically significant increased in patients compared to controls (MMP-2: 365.5±59ng/ml vs 100±27ng/ml and MMP-9: 1465±445ng/ml vs 117±44, p<0.001) and in each group separately (MMP-2 : 378ng/ml for DN group, 353ng/ml for CGN, 106ng/ml for DM, 94ng/ml for healthy group, while MMP-9 : 1591ng/ml for DN, 1338ng/ml for CGN, 133 for DM, 101ng/ml for healthy group). The mean levels for TIMPs appeared respectively decreased. Tissue inhibitor of MMP-9, TIMP-1 serum levels were 493ng/ml for the patient group and 772ng/ml for controls (375ng/ml for DN, 612ng/ml for CGN, 625ng/ml for DM and 919ng/ml for healthy controls). Tissue inhibitor of MMP-2, TIMP-2 serum levels were 119ng/ml for the patient group and 242ng/ml for controls (95ng/ml for DN, 143ng/ml for CGN, 205ng/ml for DM and 279ng/ml for healthy controls). Pearson correlation and t-test showed a significant correlation between MMPs-2 and -9 and kidney function, carotid IMT, atherosclerotic plaque, and albuminuria. Stepwise and multiple regression analysis revealed the link of MMPs-2 and -9 to atherosclerosis, albuminuria and CKD.For the five SNPs, three for MMP-2 and two for MMP-9, were also found some remarkable results. The Genotypic results from the correlation of MMPs-2 and -9 between all groups were performed by Pearson chi-square method and were statistically compared in those four groups (DN, CGN, DM and healthy controls) by Fisher exact test. Logistic regression was used to adjust for gender and age. There was a statistically increase significance for the genotype MMP9-R279Q in all four groups. In our study, patients with primary CGN that are carriers of the genotype MMP9-279Q/Q seem to be highly predisposed (about 4-20 fold!) for HT in comparison with the RR and RQ ones, whereas, for the first time, was demonstrated that the MMP9-279R/R allele acts protectively with regard to the association with HT. There was also reflected an underlying association of the same polymorphism (MMP9-R279Q) with DN, CGN and HT of IgAN, with borderline statistical significance. The MMP2-C735T polymorphism was shown to be associated with CKD, DN and atherosclerosis, while the MMP2-G1575A showed a tendancy to be associated with the patient group of CKD, with a small statistical signigficance.The expression of MMP-2 and MMP-9, measured using immunohistochemical examination, differed statistically very significantly in all types of vascular cells for all four groups in accordance with the non-parametric Friedman test. For the comparison between groups the statistically significant difference remains and increases when grouping of variables for categorical variables by Mann-Whitney test. There is also a statistical important significance for the comparison of MMPs -2 and -9 in atherosclerosis (p<0,000). Spearman correlation was performed in order to demonstrate the apparent strong expression of MMPs -2 and -9 and reduced expression to eliminate of TIMPs-1 and -2 in the patient group. In the whole of patient group (DN and CGN) MMP-2 was negatively associated with TIMP-2 statistically significantly (r: -0.427, p<0.01), while MMP-9 was very strongly negatively associated with TIMP-1, also statistically significantly (r: -0.771, p<0.01). This strong negative correlation remains in the DN group and for MMP-9 with TIMP-1 (r: -0.738, p<0.01), while in the CGN group strengthened further (MMP-2 with TIMP-2, r: -0.587, p<0.01), while for MMP-9 with TIMP-1 arrives to tend to the unit (r: -0.842, p<0.01). When the correlation is added the factor of atherosclerosis, correlations remain strong and statistically significant for MMP-2/TIMP-2 vs ATHUS (r: -0.496, p<0.01) and for MMP-9/TIMP-1 vs ATHUS (r: -0.697, p<0.01).Following animal model of intimal hyperplasia, which leads to stenosis and occlusion or immaturity of AVF, which showed increased expression of MMPs-2 and -9 at the site of arterial stenosis and venous dilatation and thrombosis, while TIMP-1 (acts protectively in atherosclerosis) exhibits reduced expression or total lack of expression, similar model is proposed to humans, according to this study.The results of the present immunohistochemical study to 66 patients showed the expression of MMPs-2 and -9 in the radial artery using immunohistochemical staining with anti-MMP-2 and anti-MMP-9 antibodies. Thus, it was demonstrated in patients with type 2 DN over 3-fold overexpression of MMP-2 in cytoplasmic intense positivity of ECs, SMCs, and FBCs. Expression was up to 3-fold more intense for MMP-9. MMPs -2 and -9 activity and expression in arterial and in arterialized vein walls may lead to structural changes in the ECM (e.g. elastin and collagen fibres), that could explain the increase in vessel diameter with ultimate result of AVF occlusion and thrombosis or inability of maturation.Of the 33 patients with DN of this study 21 showed a marked apoptosis of endothelial layer and appeared only some scattered ECs. These ECs showed a more pronounced expression of MMPs, especially MMP-9, while TIMPs-1 and -2 were not expressed. The remaining 12 patients with DN had moderate apoptosis with stripping intervals of endothelial layer. Seven of 33 patients with DN, whose fistula was thrombosed within six months and other three, whose fistula never matured, extremely strong expression of MMP-9 in the remaining ECs, in the smooth muscle cells and FBCs accompanied totally lacking expression of TIMP-1 in all three types of vascular cells.Of the 33 patients with CGN of this study 13 showed a marked apoptosis of endothelium, while 5 had partial stripping of endothelial layer.From all the above it is concluded that:Increased MMP-2 and MMP-9 serum levels are linked to the pathogenesis of albuminuria and their increase is also associated with the progression of proteinuric disease.MMPs evaluated in this study are risk factors of atherosclerosis as they increase with IMT increasing, atherosclerotic plaque expansion, and also through atherosclerotic ultrasound score (ATHUS).MMP-2 and MMP-9 act enhancing the production of biomarkers VEGF-A and TFG-β1 and therefore they contribute to the onset and evolution of sclerosis and fibrosis following chronic glomerulopathies.MMP-2 and MMP-9 are linked to the pathogenesis of DN, in mesangial proliferation through ECM degradation, vessels BM and GBM degradation, endothelial activation and apoptosis, resulting to podocytopenia and glomerular damage and ultimately chronic glomerular disease.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2017

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Dimas, Grigorios
  • Δήμας, Γρηγόριος

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/41571

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Dimas, Grigorios; Δήμας, Γρηγόριος. Ο ρόλος των μεταλλοπρωτεϊνασών-2 και -9 στην αθηροσκλήρωση των ασθενών με χρόνια νεφρική νόσο. Aristotle University Of Thessaloniki (AUTH), 2017. http://hdl.handle.net/10442/hedi/41571